May 1, 2026 · Form 4 insider transaction
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. sold 4,060,259 shares of AVLN Corp at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.
Immediately prior to the closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock and Series D Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a 19.2417-for-one basis. The Preferred Stock had no expiration date.